Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Awarded Stock Options and Restricted Stock Units
SEC Form 4
CEO of CRISPR Therapeutics, Samarth Kulkarni, receives stock options for 55,000 shares and 400,000 restricted stock units.
Summary
- Samarth Kulkarni, CEO of CRISPR Therapeutics, was granted stock options and restricted stock units on October 16, 2024.
- The stock options are for 55,000 common shares with an exercise price of $49.
- These options vest in 48 equal monthly installments starting November 16, 2024.
- Kulkarni also received 400,000 restricted stock units, each representing one share of CRSP common stock.
- These restricted stock units vest in four equal installments on October 16 of 2025, 2026, 2027, and 2028.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The grant of stock options and restricted stock units aligns the CEO's interests with those of the shareholders.
- The vesting schedules incentivize long-term performance and commitment from the CEO.
Future Outlook
The vesting schedules for both the stock options and restricted stock units suggest a focus on long-term value creation for CRISPR Therapeutics.
Industry Context
Executive compensation packages including stock options and restricted stock units are common in the biotechnology industry to attract and retain top talent and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to incentivize long-term growth.
- Companies like Vertex Pharmaceuticals and BioMarin also utilize stock options and restricted stock units as part of their executive compensation plans.
- The vesting schedules are fairly typical, with monthly vesting for options and annual vesting for restricted stock units, aligning with industry norms.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 10/16/2024 | Date of transaction: Grant of stock options and restricted stock units. |
| 11/16/2024 | First vesting date for the stock options. |
| 10/16/2025 | First vesting date for the restricted stock units. |
| 10/16/2026 | Second vesting date for the restricted stock units. |
| 10/16/2027 | Third vesting date for the restricted stock units. |
| 10/16/2028 | Fourth vesting date for the restricted stock units. |
| 10/16/2034 | Expiration date for the stock options. |
| 10/18/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.